Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052103 | 0.95 | HDAC1 (0.47) | HRH3HDAC1ALDH1A1HDAC4CHRM2 | |
| SCHEMBL14712065 | 0.94 | HRH3 (0.45) | HRH3HDAC1ALDH1A1SLC6A3MAPT | |
| SCHEMBL3054538 | 0.92 | HDAC1 (0.50) | HRH3HDAC1ALDH1A1HDAC4CHRM2 | |
| SCHEMBL3049424 | 0.90 | HDAC1 (0.51) | HRH3HDAC1ALDH1A1HDAC4CHRM2 | |
| SCHEMBL349353 | 0.89 | HDAC1 (0.42) | HRH3HDAC1ALDH1A1HDAC4MAPT | |
| SCHEMBL14790448 | 0.82 | HDAC1 (0.43) | HDAC1ALDH1A1IDO1HDAC4KDM4E | |
| SCHEMBL1121038 | 0.81 | HDAC1 (0.53) | HDAC1ALDH1A1MAPT | |
| SCHEMBL15348097 | 0.81 | PDE4A (0.39) | HRH3HDAC1ALDH1A1 | |
| SCHEMBL10112796 | 0.81 | OPRM1 (0.51) | HDAC1 | |
| SCHEMBL3486450 | 0.80 | MAPT (0.51) | HRH3ALDH1A1HDAC4CHRM3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | HRH3 140/4885HDAC1 2445/4885ALDH1A1 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.